BackFibroBiologics Overview
FibroBiologics Inc

FibroBiologics Debt to Equity

Valuation check: FBLG's debt-to-equity ratio is 0.29, above the sector sector average of 0.2.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.29

Debt to Equity

0.29

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

FibroBiologics (FBLG) FAQ

The latest debt-to-equity ratio for FBLG is 0.29. That is above the sector sector average of 0.2. Investors often review this figure alongside FibroBiologics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, FBLG currently prints 0.29 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 44.1% above the sector mean. Large gaps often invite a closer look at FibroBiologics's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.29 for FibroBiologics is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with FBLG's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting FBLG's debt-to-equity ratio (0.29), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.